Clinical Trials Logo

Filter by:
NCT ID: NCT05576194 Completed - Clinical trials for Cardiac Implantable Electronic Device Infection

Taurolidine Containing Antimicrobial CIED Wash to Prevent Infection

Start date: January 1, 2020
Phase:
Study type: Observational

From January 1st 2020, any CIED procedure conducted with adjunct TauroPace™ CIED and pocket irrigation is enrolled in a consecutive manner and followed up in one centre. Follow-up is prospectively. Before that date any CIED procedure conducted with adjunct antispetic pocket and CIED irrigation is evaluated retrospectively to form a comparable group.

NCT ID: NCT05576129 Completed - Stroke Clinical Trials

Transcranial Alternating Current Stimulation (tACS) to Improve Motor Skill Acquisition in Stroke Patients

Start date: November 14, 2022
Phase: N/A
Study type: Interventional

Hand motor function is often severely affected in stroke patients and its recovery is one primary goal in stroke rehabilitative treatment programs. Recently, theta-gamma transcranial alternating current stimulation (tACS) has been shown to enhance motor skill acquisition in healthy individuals. The aim of the present study is to examine the effect of theta-gamma tACS on motor skill acquisition in chronic stroke patients.

NCT ID: NCT05573464 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Start date: September 27, 2022
Phase: Phase 3
Study type: Interventional

This is a 12-week (with an extension to 52 weeks in a subset of participants) study comparing the safety of BGF MDI HFO twice daily (BID) with BGF MDI HFA BID in participants with moderate to very severe COPD.

NCT ID: NCT05572333 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Clinical Trial to Investigate the Safety and Tolerability of EP395 in Patients With COPD

Start date: November 22, 2022
Phase: Phase 2
Study type: Interventional

The aim of this clinical trial is to investigate the safety and tolerability of oral, once-daily EP395 administration in COPD patients for 12 weeks.

NCT ID: NCT05572138 Completed - Critical Illness Clinical Trials

Body Impedance Analysis to Detect ICUAW

BIAMI
Start date: February 8, 2023
Phase:
Study type: Observational

The aim of the study is to detect a value of muscle and organ mass measured by body impedance analysis and its correlation with the Medical Research Council (MRC) score. An MRC score ≤ 48 is defined as a diagnosis of ICU acquired weakness. The correlation of the values detected by BIA and their transfer to an MRC Score ≤ 48 will be investigated. The knowledge gained will be used for early detection of ICUAW in order to reduce the consequences of the same.

NCT ID: NCT05569317 Completed - Nurse's Role Clinical Trials

Patient-related Effects of Primary Nursing

ENGAGE
Start date: January 1, 2023
Phase: N/A
Study type: Interventional

After a one-year phase of development, primary nursing (process-responsible nursing; PP) has been practically implemented on a pilot ICU since January 2022 at the Heart and Diabetes Center NRW. PP plan, coordinate and evaluate the nursing carried out. In the further course, an examination between the project ICU and another ICU without PP with a focus on thoracic and cardiovascular surgery (surgical ICU) is to be carried out. The primary goal of this pilot study is to test the feasibility of a large-scale RCT with patient-related outcomes.

NCT ID: NCT05568979 Completed - Clinical trials for Influenza (Healthy Volunteers)

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

Start date: October 6, 2022
Phase:
Study type: Observational

This is an enhanced passive safety surveillance conducted in routine clinical care setting. Spontaneously reported ADRs will be collected by study staff following routine vaccination. The primary objective of this surveillance is to estimate the vaccinee reporting rate (RR) of suspected adverse drug reactions (ADRs) occurring within 7 days following routine vaccination with VaxigripTetra® and Efluelda®, respectively, during the Northern Hemisphere (NH) influenza season 2022/23. The secondary objectives of the study are: - To estimate the vaccinee reporting rate of suspected ADRs occurring within 7 days following routine vaccination with VaxigripTetra® and Efluelda®, respectively, according to the pre-defined age groups (not applicable for Efluelda®) - To estimate the vaccinee reporting rate of serious suspected ADRs after vaccination with VaxigripTetra® and Efluelda®, respectively, at any time following vaccination, within the EPSS

NCT ID: NCT05566639 Completed - Seasonal Influenza Clinical Trials

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Start date: September 14, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of mRNA-1010 in preventing seasonal influenza in adults 50 years and older.

NCT ID: NCT05565339 Completed - Clinical trials for Pre-existing Condition

PMEI Post-Market Clinical Follow-Up

Start date: September 29, 2020
Phase:
Study type: Observational

Confirm safety and performance of passive middle ear implants (PMEIs) in subjects with pre-existing condition which made the implantation of a MED-EL PMEI necessary

NCT ID: NCT05564117 Completed - Obesity Clinical Trials

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

OASIS 4
Start date: October 11, 2022
Phase: Phase 3
Study type: Interventional

This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily. This study will last for 72 weeks, which includes 1-week screening period, 64 weeks of treatment period and 7 weeks of follow up period.